Trial readouts
What the latest Phase 2 and Phase 3 trials reported, the effect sizes that matter, and how to read the safety signals around them.
GLP-1 Drugs and Pulmonary Hypertension
GLP-1 drugs have an observational signal in pulmonary hypertension, but no trial yet shows that retatrutide or the class treats the condition.
What retatrutide access can reveal
Lilly widened retatrutide compassionate access, but individual cases cannot replace randomized evidence on benefits, risks, or response.
Retatrutide expanded access explained
Lilly will review more requests for retatrutide expanded access, but the investigational obesity drug remains unapproved and tightly restricted.
One Retatrutide Patient Is Not a Trial
One person reportedly received retatrutide through expanded access. Here is what that means, and why it is not approval or trial evidence.
Retatrutide special access criteria
Lilly will review more retatrutide access requests, but FDA criteria, trial eligibility, company agreement, and ethics review still apply.
WIN-IND: Intas Semaglutide Trial
WIN-IND found similar 24-week HbA1c changes with Intas and reference semaglutide, but its non-inferiority rule needs clarification.
GLP-1 Patient Experiences in Jeddah
A survey in three Jeddah hospitals recorded patient concerns about GLP-1 medicines, but its cross-sectional design cannot establish causation.
Oral Semaglutide: A 25-Person Readout
A 25-person Japanese study linked oral semaglutide with lower energy intake, weight and body fat after three months, with key muscle caveats.
Semaglutide ASCVD cost model
A US veteran model found lifetime semaglutide added 1.31 QALYs but cost $118,996 per QALY at an assumed $14,000 annual price.
Facial nodules and compounded tirzepatide
One case linked facial nodules to compounded tirzepatide, but missing biopsy and cultures leave inflammation, infection and product factors unresolved.
GLP-1 drugs before surgery: what changed
A 2026 surgical review supports risk-based planning for semaglutide and tirzepatide, but it reports no new trial or aspiration rate.
Incretin weight loss in type 1 diabetes
A 70-person study linked liraglutide, semaglutide, or tirzepatide treatment with fat loss, modest lean loss, and stable total-body bone density.